Immunogenicity and Protective Efficacy of a Polyvalent DNA Vaccine against Human Orthopoxvirus Infections Based on Smallpox Virus Genes
Figure 5
The survival rates of BALB/c mice after triple intracutaneous immunization with the polyvalent DNA vaccine pcDNA-A30L, pcDNA-F8L, pcDNA-M1R, pcDNA-A36R, and pcDNA-B7R (pcDNA-Σ5) or triple intraperitoneal immunization with the polyvalent DNA vaccine pBKRSV-A30L, pBKRSV-F8L, pBKRSV-M1R, pBKRSV-A36R, and pBKRSV-B7R (pBKRSV-Σ5) and intraperitoneal challenge with ectromelia virus strain K1 at a dose of 10 LD50. 30 mice in each group were challenged 3 weeks after the last immunization.
